Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.

A prospective cohort of 100 people with stage II or III resectable gastric cancer collected tumor and perioperative plasma to test whether ctDNA after adjuvant chemotherapy predicted recurrence. The abstract does not name the assay.

Cancer CommunicationsPubMed 37837629DOI 10.1002/cac2.12494